News Kineta, Inc.

Equities

KA

US49461C1027

Delayed Nasdaq Other stock markets 01:12:24 2024-05-10 pm EDT			5-day change	1st Jan Change
0.595 ^USD	-4.80%		+0.86%	-83.61%

Apr. 08	Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	CI
Mar. 21	Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial	Apr. 08	AQ
Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	Apr. 08	CI
Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M	Mar. 21	MT
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update	Mar. 21	AQ
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported	Mar. 12	AQ
Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123	Mar. 12	CI
Top Midday Decliners	Feb. 29	MT
Kineta Announces Restructuring and Exploration of Strategic Alternatives	Feb. 29	AQ
Kineta, Inc. Terminates Employment of Pauline Kenny as General Counsel and Secretary	Feb. 29	CI
Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO	Feb. 29	CI
Kineta, Inc. Announces Restructuring and Workforce Reduction	Feb. 29	CI
Kineta Announces Exploration of Strategic Alternatives	Feb. 28	CI
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium	Feb. 22	AQ
Kineta to Present at Upcoming Investor Conferences	Feb. 14	AQ
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series	Feb. 07	AQ
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors	Jan. 17	AQ
Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity	Jan. 17	CI
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event	Jan. 04	AQ
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer	Dec. 13	AQ
Kineta to Present at the Life Sciences Investor Forum December 14th	Dec. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kineta, Inc.

Equities

KA

US49461C1027

Summary

Filters